Clinical trial

Double-blinded Randomized Controlled Trial Investigating the Effectiveness of Vitamin D Supplementation in Patients With End-stage Knee Osteoarthritis

Name
2022.252
Description
Osteoarthritis (OA) knee is one of the commonest chronic degenerative conditions. It causes disability in elderlies due to pain and stiffness. The prevalence of radiologic knee osteoarthritis increases in proportion to age, reaching an astounding 64.1% for patients who are over 60 years of age. In 2021, there were over 26,000 patients on the Hospital Authority (HA) waiting list for knee total knee replacement (TKR) and with only 4300 TKRs performed, the nominal waiting time for TKR was almost 89 months. Low vitamin D can adversely affect cartilage thickness and study suggested that low serum vitamin D is associated with increased radiographic knee OA progression. A systematic review concluded that vitamin D supplements can improve pain and function in patients with knee OA. Vitamin D has long been recognized for its effect on musculoskeletal health and increasing attention has been focused for its effect on muscle function. Vitamin D have a direct effect on muscle hypertrophy by acting on specific vitamin D receptors (VDRs) on myocytes, and sufficient levels of vitamin D in patients have been found to correlate with an increase in the size, number, and strength of muscle fibres. Vitamin D also seems to exert beneficial effects by its interplay with myokines such as myostatin and irisin. One study also showed that muscle nuclear VDR was increased by 30% and augmented muscle fibre size by 10% in elderly females (mean age of 78 years) taking vitamin D orally at a rate of 100 µg/day (4000 IU/day) for 4 months. This will be a double-blinded RCT investigating the effect of vitamin D supplements or knee muscle strength, physical function, pain symptoms and, sarcopenia status. The study will be a follow-up study with assessment at baseline, 3- ,6-and 12-months post vitamin D intervention.
Trial arms
Trial start
2024-03-17
Estimated PCD
2025-06-30
Trial end
2025-11-30
Status
Recruiting
Treatment
Vitamin D
4000IU/day vitamin D supplement will be used for 6 months
Arms:
Intervention group
Other names:
SODX Co., Ltd, Osaka, Japan
Placebo
Placebo will be used for 6 months
Arms:
Control group
Other names:
SODX Co., Ltd, Osaka, Japan
Size
56
Primary endpoint
Quadriceps and hamstring muscle strength assessment
Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Eligibility criteria
Inclusion Criteria: * Male and female patients aged over 50 with end-stage knee OA * Patient are on the waiting list for TKR at Prince of Wales Hospital * Walk unaided for 6 meters * Able to comply with the assessments and has given oral and written consent * Patients with vitamin D insufficiency and deficiency at the baseline measurement (25(OH)D \<30 ng/mL) Exclusion Criteria: * Patients with connective tissue disorders or myositis condition * History of any Hip \& Knee surgery * Patients with malnutrition were assessed by Mini-Nutritional assessment. * Patients with acute immobility (i.e., post-hip fracture or post-acute hospital admission) * Patient scheduled for TKR within six months * Patients already taking vitamin D supplements * Patients with a known contraindication to vitamin D treatment (such as allergy) * Patients who have renal impairment with glomerular filtration rate (eGFR) \< 30 ml/minute
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 56, 'type': 'ESTIMATED'}}
Updated at
2024-03-27

1 organization

2 drugs

3 indications

Indication
Sarcopenia